【MGRC 0155 交流专区】基因组学资源

icy97

Announcement Date	Financial Year	Quarter Number	Financial Quarter	Revenue (RM,000)	Profit Before Tax (RM,000)	Net Profit (RM,000)	Earning Per Share (Cent)	Dividend (Cent)	NTA (RM)
27/08/2013	30/06/2013	4	30/06/2013	257	-756	-766	-0.81	0.00	0.210
10/05/2013	30/06/2013	3	31/03/2013	169	-2,350	-2,356	-2.50	0.00	0.220
22/02/2013	30/06/2013	2	31/12/2012	52	-2,886	-2,897	-3.08	0.00	0.250
19/11/2012	30/06/2013	1	30/09/2012	58	-2,761	-2,782	-2.96	0.00	0.280
28/08/2012	30/06/2012	4	30/06/2012	1,068	-1,581	-1,603	-1.70	0.00	0.310
22/05/2012	30/06/2012	3	31/03/2012	2,330	-1,055	-1,077	-1.14	0.00	0.330

http://www.malaysiastock.biz/Corporate-Infomation.aspx?type=A&value=M&securityCode=0155

公司官网：http://www.mgrc.com.my/

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/06/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/06/2013	30/06/2012	30/06/2013	30/06/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	257	1,068	536	9,843
2	Profit/(loss) before tax	-756	-1,581	-8,753	-3,544
3	Profit/(loss) for the period	-766	-1,603	-8,801	-3,660
4	Profit/(loss) attributable to ordinary equity holders of the parent	-766	-1,063	-8,801	-3,660
5	Basic earnings/(loss) per share (Subunit)	-0.81	-1.70	-9.35	-3.89
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2148		0.3084

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2013	30/09/2012	30/09/2013	30/09/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	605	58	605	58
2	Profit/(loss) before tax	-1,728	-2,761	-1,728	-2,761
3	Profit/(loss) for the period	-1,736	-2,782	-1,736	-2,782
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,736	-2,782	-1,736	-2,782
5	Basic earnings/(loss) per share (Subunit)	-1.84	-2.96	-1.84	-2.96
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1942		0.2127

师兄

什么公司来的？

icy97

基因组学543万购Clinipath

财经 2013年12月21日
（吉隆坡21日讯）基因组学中心（MGRC，0155，创业板）旗下联营公司--MPath私人有限公司与Azalea控股私人有限公司达成买卖协议（SPA），以543万令吉的价格收购Clinipath（大马）私人有限公司共90万股或占缴足资本30%的股权。       

MPath是由基因组学中心与Ajmaks私人有限公司共同持有的联营公司，双方各持有50%权益。

至於Clinipath（大马），则是一家以提供病理及临床检验服务为主要业务的公司。基因组学中心早在去年6月买进该公司的65%股权，若上述收购案完成將会把持股率提高至95%。

管理层预测，上述股权收购可在60天內完成。[东方日报财经]

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Admission Sponsor	Kenanga Investment Bank Bhd
Sponsor	Same as above

Type	Announcement
Subject	OTHERS
Description	MALAYSIAN GENOMICS RESOURCE BERHAD (“MGRCB” OR “THE COMPANY”) PROPOSED ACQUISITION OF UP TO 30% EQUITY STAKE IN CLINIPATH (MALAYSIA) SDN BHD (“CM”) FOR A CASH CONSIDERATION OF AN AMOUNT EQUIVALENT APPROXIMATELY TO RM5,429,188.22 BY MPATH SDN. BHD., AN ENTITY JOINTLY CONTROLLED BY AJMAKS SDN BHD (“AJMAKS”) AND MGRCB (“PROPOSED ACQUISITION”)
INTRODUCTION The Board of Directors of MGRCB (“Board”) wishes to announce that MPath Sdn Bhd (“MPath” or “the Buyer”), an entity jointly controlled by Ajmaks Sdn Bhd (“AJMAKS”) and MGRCB, had on 19 December 2013 agreed to the terms and entered into a sale and purchase agreement (“SPA”) with Azalea Holdings Pty Ltd (“AHPL” or “the Seller”) for the acquisition of 900,000 ordinary shares of RM1.00 each representing 30% of the total issued and paid up share capital of CM (“Sale Shares”) for a consideration of Australian Dollars (“AUD”) that is equivalent to RM5,429,188.22. On 20 July 2012, MGRCB had announced the acquisition by MPath of 65% of CM. Following the Proposed Acquisition, MPath will own 95% of the total issued and paid up share capital of CM. DETAILS OF THE PROPOSED ACQUISITION (a)        Information on MPATH MPath (Company No. 989676-H) is a private limited company incorporated in Malaysia under the Companies Act, 1965 on 7 May 2012. The present authorised share capital of MPath is RM100,000.00 divided into 100,000 ordinary shares of RM1.00 each. MPATH is a 50:50 joint venture company of MGRCB and Ajmaks Sdn. Bhd. (“AJMAKS”). AJMAKS is a subsidiary of Qualitas Healthcare Corporation Sdn Bhd, which is in the business of providing primary healthcare services in Malaysia. The principal activities of MPath is investment holding. (b)        Information on the AHPL AHPL (Company no.: 074 968 344) is a corporation organised and existing under the laws of the State of Western Australia; and AHPL is the registered shareholder and beneficial owner of the Sale Shares. The principal activity of AHPL is a holding company. (c)        Information on CM CM (Company No 248187-W) is a private company limited by shares incorporated in Malaysia with an authorised share capital of RM5,000,000 divided into 5,000,000 ordinary shares of RM1.00 each of which 3,000,000 ordinary shares have been issued and are fully paid and credited as fully paid. CM carries on the business of providing pathological and medical laboratory services. The summary of the financial information of CM based on the audited results for the financial period ended (“FPE”) 30 June 2013 is as follows: Audited FPE 30 June 2013* RM Revenue 13,592,400 Profit before taxation 793,449 Profit after taxation 684,771 Profit after taxation and minority interest 684,771 Net assets/shareholders' fund 7,058,233 Total borrowings nil Note: *        8 months pursuant to a change in the financial year-end of CM from 31 October to 30 June (d)        Basis and justification of the Purchase Consideration The purchase consideration of the AUD equivalent approximately to RM5,429,188.22 for the Proposed Acquisition was arrived at on a "willing buyer and willing seller" basis after taking into consideration, amongst others, the current financial performance, net book value and future prospects of CM as mutually agreed upon by the parties. The price per share is equal to the price per share paid when MPath acquired the 65% interest in CM in 2012. The basis for valuation of the said acquisition was determined from the perspective of a single merged special purpose vehicle, MPath, that would collectively own the assets and operate them as a going concern and were valued from an earnings perspective to arrive at the valuation. Justification for the final purchase determination is as follows: MGRCB has evolved from a pure IT services company prior to listing, to offering both IT and lab-based services following its listing on the ACE Market of Bursa Malaysia Securities Berhad (“Bursa”) in October 2010. Since then, its portfolio of products and services targeting healthcare has continued to evolve, as evidenced by the launch of Genetic Screening Services ("GSS")announced in June 2011. The Proposed Acquisition continue the initiative by providing MGRCB with an established market with which to commercialise these new products. In addition to this, MGRCB will benefit from the reputation of CM amongst healthcare providers, the ISO certified laboratory, established sales force and finally the nationwide logistics network. Namely, CM offers a network of: 5 hospitals and specialist centres for which in-house laboratory services are completely managed and operated on-site by CM; in excess of 600 doctors served in Peninsular and East Malaysia; and 18 locations for collection of samples throughout the country, each with different capabilities in terms of laboratory infrastructure and serving as a collection centre for the main laboratory located in Klang Valley. 2.        No suitable peer could be identified from local IT companies listed on Ace Market of Bursa. By the same measure, no suitable peer could be identified for healthcare or lab related services. SALIENT TERMS OF THE SPA The Consideration shall be the AUD equivalent of RM5,429,188.22. The Buyer shall notify the Seller of the proposed AUD equivalent on the date of payment and the Seller shall be provided four (4) hours to approve the exchange rate quoted or suggest an alternate bank and exchange rate then available in Kuala Lumpur for use by the Buyer. The date of completion shall occur within sixty (60) days after all the conditions precedent to the sale of shares have been met or waived. The Consideration shall be paid to the Designated Account as notified by the by the Seller. Upon receipt of the Consideration by the Seller, the beneficial ownership in the Sale Shares shall vest in the Buyer and the Seller shall, until the registration of the Buyer in the Company’s register of members as the registered owner of the Sale Shares, hold the Sale Shares as bare trustee of the Buyer. The Seller may terminate the SPA with immediate effect by written notice to the Buyer and may instruct the Escrow Agent to return the Escrow Documents in the event where Consideration is not received within sixty (60) days after the date of the SPA or other date as the Parties may agree in. PROSPECTS OF CM The prospects of CM are the same as when MPath purchased the initial 65% interest in CM, only better given that MGRCB and AJMAKS will own 95% upon completion of the Proposed Acquisition. Traditional pathology and, molecular screening and diagnostics are two services with overlapping characteristics. These include the industry they operate in (i.e. healthcare), service category (i.e. medical laboratory services and analysis of biological samples), distribution channels, target customers, chain of processes and ISO certification (i.e. ISO 15189:2007). As such, the businesses of CM and MGRCB are complementary in nature. The merger between the two companies will enable such strong synergies to distinguish themselves as one exceptionally effective industry player. Given CM’s stronger presence in the healthcare industry, it will be the platform for MGRCB to expedite its GSS through the readily available network of distribution channels and to expedite CM's laboratory management expertise. The highly specialised ability to interpret and analyse genetic and other molecular data accumulated over the years at MGRCB will lend to the advancement of services currently offered by CM. Besides being much faster than culture-based diagnostic approaches, molecular screening and diagnostics provides advantages beyond the abilities of traditional pathology such as detecting fastidious or uncultivable agents, low concentrations of pathogens, and antibiotic and antiviral drug resistance in patients’ biological samples. These are amongst the many important capabilities to leverage CM’s position as the more advanced medical laboratory service provider in the country. More crucial is that these advanced services and know-how are readily available within the country for CM at MGRCB, as opposed to competitors who currently have to work with foreign partners for molecular diagnostics tests which result in longer turnaround time. With the growing role of technology and the public’s awareness of healthcare and wellness, the Directors anticipate the volume of transactions via the enlarged MGRCB group of companies' (“MGRCB Group”) medical laboratory services, via MPath, to increase accordingly. Synergies between the various entities will enable the Group to capture tomorrow’s market, today. FINANCIAL EFFECTS OF THE PROPOSED ACQUISITION (a) Share Capital and substantial shareholders’ shareholdings The Proposed Acquisition will not have any effect on the issued and paid-up share capital and substantial shareholders' shareholding of the Company as the Proposed Acquisition will not involve any share issuance by the Company. (b)        Earnings, Net Assets and Gearing The Proposed Acquisition will not have any material effect on the earnings, net assets and gearing of the MGRCB Group for the current financial year ending 30 June 2014. SOURCES OF FUNDING The Proposed Acquisition shall be financed by cash contributions from the shareholders of MPath, namely MGRCB and AJMAKS, in the form of shareholder advances and/or a subscription for shares in MPath on an equal basis and/or commercial loans. As at the date of this announcement, the proportion between the above-mentioned sources of funding to finance the Proposed Acquisition has not been determined. LIABILITIES TO BE ASSUMED In so far as the Board is aware, save for the liabilities which may arise from the shareholders’ advances and/or commercial loans, there are no liabilities, including contingent liabilities and guarantees, to be assumed by Company arising from the Proposed Acquisition. APPROVAL REQUIRED The highest percentage ratio applicable to the Proposed Acquisition pursuant to paragraph 10.02(g) of the ACE Market Listing Requirements of Bursa is 15%. The Proposed Acquisition is not subject to shareholders' approval or any regulatory approval. DIRECTORS’AND MAJOR SHAREHOLDERS’ INTEREST In so far as the Directors of MGRCB are aware, none of the Directors and/or major shareholders and/or persons connected to the Directors or major shareholders of the Company has any interest, direct or indirect, in the Proposed Acquisition. RATIONALE FOR THE PROPOSED ACQUISITION The rationale presented for the original acquisition of 65% interest in CM last year remain as valid for the Proposed Acquisition. In addition to these, MGRCB and AJMAKS are desirous of realizing the gains from their joint efforts in building the business and revenues from CM. Beyond recognizing the share of profits from the jointly controlled entity, MGRCB and AJMAKS would like to improve their cash positions via a distribution of dividends via CM to MPath, and subsequently to MGRCB and AJMAKS in the form of dividends or via a redemption of preference shares. CM is generating net profits and has a significant amount of undistributed retained earnings from which dividends can be paid as revenues improve. For these reason, the additional 30% equity in CM represents a tangible source for future cash flow greater than the opportunity cost of the proposed acquisition. RISK FACTORS General Business RisksLike all businesses, CM is not insulated from general business risks inherent in the industry in which it operates. These include a downturn in the economy, entry of new players, constraints in skilled labour supply, increase in labour costs, changes in law and tax legislation affecting the healthcare industry and adverse changes to general business and credit conditions. Although the MGRCB will seek to mitigate these risks through, inter alia, prudent management policies, active research and development, securing and maintaining good business relationships with its customers and suppliers, and effective human resource management, no assurance can be given that any or all of the above risk factors will not have material adverse effects on its business performance or prospects, as well as its financial position. CompetitionThe pathology sector in Malaysia consists of only a few players. Some of these companies serve the whole healthcare industry, including providing direct-to-consumer services, while the rest exclusively serve hospitals and medical practitioners within their own group of companies. Despite the inherent rivalry risk, the Board is confident that MGRCB will be able to maintain its competitive advantage by focusing on providing innovative and high value-added services, continuous product development and improvement, prompt and efficient delivery of services and effective cost controls. Despite the above measures being taken, no assurance can be given that MGRCB will be able to maintain and/or expand their market share in the future.Acquisition Risks MGRCB could encounter difficulties arising from the Proposed Acquisition, including unanticipated integration problems and business disruption which may result in unforeseen operating difficulties and expenditures. Moreover, the expected benefits of the Proposed Acquisition may not be realised, to such extent that MGRCB may be required to write-off certain associated acquisition costs such as goodwill and other intangible assets, which could be significant.Financing RiskIt is the intention of MGRCB that the Proposed Acquisition will be financed partly by bank borrowings. Therefore, MGRCB may be subjected to the risk of fluctuation of interest rates as well as the risk of having to generate sufficient funds to meet its financial repayment commitments on time. To mitigate against such risks, MGRCB Group will continue to monitor closely the interest rate movements and adopt cost-effective financing packages as it deems appropriate. DIRECTORS’ STATEMENT The Board after having considered all aspects of the Proposed Acquisitions (including but not limited to the rationale and financial effects) is of the opinion that the terms of the Proposed Acquisitions are fair, reasonable and on normal commercial terms and are not detrimental to the interest of the minority shareholders. The Board is also of the opinion that the Proposed Acquisitions is in the best interests of MGRCB. ESTIMATED COMPLETION Barring unforeseen circumstances, the Proposed Acquisition is expected to be completed no later than sixty (60) days from the date of the SPA. DOCUMENTS FOR INSPECTION The SPA shall be available for inspection at the registered office of the Company at Level 7, Menara Milenium, Jalan Damanlela, Pusat Bandar Damansara, Damansara heights, 50490 Kuala Lumpur, Wilayah Persekutuan during normal office hours on any weekday (except public holiday) for a period of three (3) months from the date of this announcement. The announcement is dated 19 December 2013.

icy97

Admission Sponsor	Kenanga Investment Bank Bhd
Sponsor	Same as above

Type	Announcement
Subject	OTHERS
Description	MALAYSIAN GENOMICS RESOURCE BERHAD (“MGRCB” OR “THE COMPANY”) - ACQUISITION OF UP TO 30% EQUITY STAKE IN CLINIPATH (MALAYSIA) SDN BHD (“CM”) FOR A CASH CONSIDERATION OF AN AMOUNT EQUIVALENT APPROXIMATELY TO RM5,429,188.22 BY MPATH SDN. BHD., AN ENTITY JOINTLY CONTROLLED BY AJMAKS SDN BHD (“AJMAKS”) AND MGRCB (“ACQUISITION”)
With reference to the announcement made on 19 December 2013 in relation to the Aquisition, the Board of Directors of MGRCB wishes to announce that the Aquisition has been completed on Monday, 17 February 2014. Following the completion of the Acquisition, MPath Sdn. Bhd., the 50:50 jointly controlled entity of MGRCB and AJMAKS, now owns 95% of the total issued and paid up share capital of CM. This announcement is dated 17 February 2014.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2013	31/12/2012	31/12/2013	31/12/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,383	52	1,988	110
2	Profit/(loss) before tax	-832	-2,886	-2,560	-5,647
3	Profit/(loss) for the period	-839	-2,897	-2,575	-5,679
4	Profit/(loss) attributable to ordinary equity holders of the parent	-839	-2,897	-2,575	-5,679
5	Basic earnings/(loss) per share (Subunit)	-0.89	-3.08	-2.74	-6.04
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1853		0.2127

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/03/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/03/2014	31/03/2013	31/03/2014	31/03/2013

1	Revenue	423	169	2,411	279
2	Profit/(loss) before tax	-1,956	-2,350	-4,516	-7,997
3	Profit/(loss) for the period	-1,961	-2,356	-4,536	-8,035
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,961	-2,356	-4,536	-8,035
5	Basic earnings/(loss) per share (Subunit)	-2.08	-2.50	-4.82	-8.54
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1645		0.2127

icy97

基因组学土展保健 探讨商业开发合作

财经新闻 财经  2014-06-29 11:28
（吉隆坡28日讯）基因组学资源（MGRC，0155，创业板）周四在美国与联邦土地发展局保健（Felda Wellness，简称土展保健），签署了解备忘录探讨商业开发合作。

该公司通过文告表示，这将预示着双方在热带有机体基因排列的科学，技术和商业开发的合作。【南洋网财经】

Admission Sponsor	Kenanga Investment Bank Bhd
Sponsor	Same as above

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" or "the Company") - MEMORANDUM OF UNDERSTANDING BETWEEN FELDA WELLNESS CORPORATION SDN. BHD. AND THE COMPANY
The Board of Directors of MGRC wishes to announce that the Company has, on 26 June 2014 at the Bio International Convention held in San Diego, California, United States of America, entered into a Memorandum of Understanding (“MOU”) with Felda Wellness Corporation Sdn Bhd.  The envisaged collaboration encompasses the scientific, technological and commercial exploration of the genomes of tropical organisms. None of the Directors or major shareholders of MGRC and/or persons connected with them, have any interest, direct or indirect, in the MOU. The Board of Directors of MGRC, having considered all aspects of the MOU, is of the opinion that the MOU is in the best interests of the MGRC Group of companies. This announcement is dated 27 June 2014.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/06/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/06/2014	30/06/2013	30/06/2014	30/06/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	2,000	257	4,411	536
2	Profit/(loss) before tax	237	-958	-4,279	-8,955
3	Profit/(loss) for the period	234	-968	-4,302	-9,003
4	Profit/(loss) attributable to ordinary equity holders of the parent	234	-968	-4,302	-9,003
5	Basic earnings/(loss) per share (Subunit)	0.25	-1.03	-4.57	-9.57
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1670		0.2127

icy97

基因组学获1900万合约

财经新闻 财经  2014-11-05 10:17
（吉隆坡4日讯）基因组学资源（MGRC，0155，创业板）宣布，获得土展局保健（Felda Wellness）颁发服务合约，总值1900万令吉。

公司将为土展局保健提供研发服务，即把植物配方制成保健品、化妆品与营养品。

土展局保健在此项目，共注入了1900万令吉，并预计在2017年1月完成。

两家公司曾在2014年6月27日，针对此项目签署了解备忘录。【南洋网财经】

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Type	Announcement
Subject	OTHERS
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" or "the Company") - PROJECT AGREEMENT
The Board of Directors of MGRC wishes to announce that MGRC had on 3 November 2014, signed a project agreement with Felda Wellness Corporation Sdn Bhd ("FWC") for the provision of services relating to the research and development of plant-derived compounds for commercial applications in human health, cosmetics and nutrition (“Project”). A total of RM19 million has been allocated by FWC for the Project, which is expected to be completed by January 2017. The project was awarded pursuant to the Memorandum of Understanding dated 26 June 2014 and announced on 27 June 2014. This announcement is dated 4 November 2014.

icy97

Type	Reply to query
Reply to Bursa Malaysia's Query Letter - Reference ID	NM-141106-43397
Subject	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" or "the Company") - PROJECT AGREEMENT
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" or "the Company") - PROJECT AGREEMENT
Unless otherwise stated, all definitions and terms used in this announcement shall have the same meaning as those defined in the announcement dated 4 November 2014 in relation to the Project Agreement Reference is made to the query letter received from Bursa Malaysia Berhad on 6 November 2014 pertaining to the above matter. The Board of Directors of MGRC wishes to announce the following additional information:- 1) The effect of the Project on the earnings per share and net assets per share of MGRC Group. The Project with Felda Wellness Corporation Sdn Bhd is expected to have a positive effect on the earnings per share and net assets per share of MGRC group over the duration of the project period. 2) The risks in relation to the Project. At this point in time, the Company is not aware of any material risks in relation to the Project. 3) Whether the directors and/or major shareholders and/or persons connected with a director or major shareholder have any interest, direct or indirect, in the Project and the nature and extent of their interests. The directors and/or major shareholders and/or persons connected with a director or major shareholder do not have any interest in the Project. This announcement is dated 7 November 2014.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2014	30/09/2013	30/09/2014	30/09/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	2,557	605	2,557	605
2	Profit/(loss) before tax	498	-1,728	498	-1,728
3	Profit/(loss) for the period	497	-1,736	497	-1,736
4	Profit/(loss) attributable to ordinary equity holders of the parent	497	-1,736	497	-1,736
5	Basic earnings/(loss) per share (Subunit)	0.53	-1.84	0.53	-1.84
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1567		0.1514

icy97

訂單營收雙位數增長‧大馬基因資源有望轉盈

2014-12-10 16:59      
（吉隆坡10日訊）大馬基因資源（MGRC,0155,創業板科技組）訂單與營收雙位數增長，2015財政年有望轉虧為盈。

該公司首席營運員諾丁在股東大會後向記者表示，公司6月份的訂單與銷售額為620萬及1千100萬令吉，而12月份已經分別增長至2千500萬及1千200萬令吉。

“公司目前與7家公司簽訂了總值1千900萬令吉的訂單，該批訂單以農業項目為主，且足以讓公司未來2年內忙碌這些訂單，相信在本財政年內可轉虧為盈。”

他說，公司目前共有11所化驗中心為2千名醫生及7所醫療中心服務。未來3年內會增多7至10家醫療中心提高相關服務，以創造更多的營收。

他表示，2018年時，全球的基因資源數據分析的市值可達80億至120億美元（約272億至408億令吉），每年將以21%的速度成長。2014年大馬基因資源的總市值則為4億2千800萬令吉，而公司佔有6%的市佔率，希望在2019年的市佔率可達10%，屆時的總市值約7億5千400萬令吉。

看好印尼菲律賓市場

“公司目前看好印尼及菲律賓的市場，並積極尋找市場策略夥伴，以更好推廣公司的業務。”

他補充，公司目前的營收是分析服務（Analytical Services）、病理實驗室（Pathology Lab）及檢查服務（Screening Services），2017財政年公司會將業務擴增至診斷服務（Diagnostic Services），屆時營收的比例將會是64、20、8及5%。

“診斷服務預計在2020年將會達到800億美元的營收，而公司將會與歐美地區的實驗室建立夥伴關係，並將最好技術引進大馬，以設置在各個醫療中心，這是一個相當不錯的機會。”（星洲日報／財經）

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2014	31/12/2013	31/12/2014	31/12/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,693	1,383	6,250	1,988
2	Profit/(loss) before tax	1,355	-832	1,853	-2,560
3	Profit/(loss) for the period	1,353	-839	1,850	-2,575
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,353	-839	1,850	-2,575
5	Basic earnings/(loss) per share (Subunit)	1.44	-0.89	1.97	-2.74
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1711		0.1514

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2015	31 Mar 2014	31 Mar 2015	31 Mar 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	4,293	423	10,543	2,411
2	Profit/(loss) before tax	1,298	-1,956	3,151	-4,516
3	Profit/(loss) for the period	1,296	-1,961	3,146	-4,536
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,296	-1,961	3,146	-4,536
5	Basic earnings/(loss) per share (Subunit)	1.38	-2.08	3.34	-4.82
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1849		0.1514

icy97

icy97 发表于 18-2-2014 12:51 AM

Type	Announcement
Subject	OTHERS
Description	ACQUISITION OF REMAINING 5% EQUITY IN CLINIPATH (MALAYSIA) SDN BHD FOR A CASH CONSIDERATION OF RM904,865 BY MPATH SDN BHD, AN ENTITY JOINTLY CONTROLLED BY AJMAKS SDN BHD AND MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC") (ACQUISITION)
Further to the announcement made on 17 February 2014, the Board of Directors of MGRC wishes to announce that MPath Sdn. Bhd. ("MPATH") has acquired the remaining 5% equity in Clinipath (Malaysia) Sdn. Bhd. ("CM") for a cash consideration of RM904,865. Following the completion of the Acquisition, CM is now a wholly owned subsidiary of MPATH. This announcement is dated 2 June 2015.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2015	30 Jun 2014	30 Jun 2015	30 Jun 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,355	2,000	13,898	4,411
2	Profit/(loss) before tax	478	237	3,629	-4,279
3	Profit/(loss) for the period	477	234	3,623	-4,302
4	Profit/(loss) attributable to ordinary equity holders of the parent	477	234	3,623	-4,302
5	Basic earnings/(loss) per share (Subunit)	0.51	0.25	3.85	-4.57
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1875		0.1514

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2015	30 Sep 2014	30 Sep 2015	30 Sep 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,599	2,557	3,599	2,557
2	Profit/(loss) before tax	906	498	906	498
3	Profit/(loss) for the period	906	497	906	497
4	Profit/(loss) attributable to ordinary equity holders of the parent	906	497	906	497
5	Basic earnings/(loss) per share (Subunit)	0.96	0.53	0.96	0.53
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1972		0.1876

icy97

MGRC扩展业务至医疗保健

财经  2015年12月10日
（吉隆坡10日讯）基因组学中心（MGRC，0155，创业板）未来將著重扩展其业务至医疗保健领域，进而提升该公司营收表现。基因组学中心將联同医疗公司筹办一系列讲座会和工作坊，提高本地医生对基因组学的知识及民眾意识。

该公司合作伙伴包括班底医院、柔佛医药保健（KPJ，5878）和其他小型私人诊所。

该公司首席营运员萨沙诺丁在股东大会后的媒体匯报会上解释，「大马医生根据病例试验作出临床决策的比例，远低于发展国家，预示著基因组学在医疗保健领域的发展空间甚大。」

他指出，在发展国家中，有70%的临床决策，是通过病例试验结果而做出的，然而，在大马这个比例只有约为45%至50%。

他也表示，看好人口眾多的东南亚国家，医疗保健领域拥有良好的发展前景。

展望未来，基因组学中心有意在菲律宾寻找商业伙伴或进行资產收购，他认为，当地拥有较多美国医疗企业，对于基因组学的意识较高。同时，该公司也计划在香港收购资產。

手持订单740万

基因组学中心目前在印尼、泰国和香港皆有业务，其中大马和印尼的营运贡献比重相同。该公司截至2015年11月的手持订单和销售量，分別达740万令吉和900万令吉。

另一方面，基因组学中心2015財政年（6月30日结账）转亏为盈，当中解析服务（Analytical Service）佔整体营业额的86%，其余则来自病理研究（Pathology Lab）以及筛查服务（Screening Services），2项业务各贡献6%和8%营业额。

该公司计划在2017年將业务多元至诊断服务（Diagnostic Services），並冀望于2019財政年推高其病理研究营业额贡献至16%，而筛查服务和诊断服务则各佔8%。

隨著上述3项业务壮大，营业额贡献增长，解析服务对2019年財政年的营业额贡献料减低至68%，但仍是基因组学中心的核心业务。【东方网财经】